BRAF/MEKi combinations, including dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib, are associated with high objective response rates (ORRs), in the order of 70%, for advanced BRAF-mutant melanoma [4–6]. This evidence concerns the gene BRAF and melanoma.